Review
Chemistry, Multidisciplinary
DaeYong Lee, Kristin Huntoon, Yifan Wang, Wen Jiang, Betty Y. S. Kim
Summary: The discovery of immune checkpoint blockade has revolutionized cancer treatment, but current immunotherapies are only effective for a small subset of patients. Future advancements in cancer immunotherapy will focus on developing novel therapeutic molecules or immunoengineered cells. Biomaterials can efficiently reprogram and recruit immune cells in tumors to activate T cell immunity against advanced cancers.
ADVANCED MATERIALS
(2021)
Article
Oncology
Marc Pfefferle, Irina L. Dubach, Raphael M. Buzzi, Elena Duerst, Nadja Schulthess-Lutz, Livio Baselgia, Kerstin Hansen, Larissa Imhof, Sandra Koernig, Didier Le Roy, Thierry Roger, Rok Humar, Dominik J. Schaer, Florence Vallelian
Summary: The study revealed that CD40 signaling in Clec4f(+) Kupffer cells triggers anti-CD40 antibody-induced liver toxicity. However, controlled erythrophagocytosis and the linked anti-inflammatory signaling by the endogenous metabolite heme can be exploited to reprogram liver macrophages and prevent necroinflammatory liver disease caused by high-dose administration of anti-CD40 antibodies.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Oncology
Ronan Talty, Kelly Olino
Summary: Both cancer cells and immune cells rely on specific metabolic programs for survival and function, with immune cells having the capability to either enhance or suppress the antitumor immune response based on metabolic changes. The shared microenvironment within tumors affects the metabolism of immune cells and can impact the efficacy of immunotherapies, highlighting the importance of understanding the interplay between metabolism, immune response, and cancer progression.
Article
Oncology
Bin-Jin Hwang, Li-Chung Tsao, Chaitanya R. Acharya, Timothy Trotter, Pankaj Agarwal, Junping Wei, Tao Wang, Xiao-Yi Yang, Gangjun Lei, Takuya Osada, Herbert Kim Lyerly, Michael A. Morse, Zachary Conrad Hartman
Summary: This study demonstrates that the suppression of innate immune gene expression in tumor cells is a major factor contributing to the insensitivity of colorectal cancer to immune checkpoint inhibitor treatment. By reintroducing the suppressed gene MAVS, the study found that it can stimulate both local and systemic immune responses against the tumor and enhance the efficacy of anti-tumor immunotherapy when combined with PD-L1 inhibitors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Bernd Heinrich, Firouzeh Korangy
Summary: Innate lymphoid cells (ILCs) are a heterogeneous population of the innate immune system that play a crucial role in maintaining immune homeostasis. They exhibit high plasticity, allowing them to quickly respond to changes in their microenvironment. ILCs can transdifferentiate into different subsets in the tumor microenvironment, influencing the immune response and tumor therapy. This review summarizes the functional and plastic heterogeneity of ILCs in homeostasis and disease, with a focus on tumor-driven plasticity and the impact of ILC-induced inflammation on the tumor microenvironment and anti-tumor immunity.
FRONTIERS IN IMMUNOLOGY
(2022)
Editorial Material
Biochemistry & Molecular Biology
Nobunao Ikewaki, Gene Kurosawa, Tomohiko Kisaka, Samuel J. K. Abraham
Summary: This article highlights the potential of beta-glucans as nonspecific immunostimulatory adjuvants to enhance innate immune response and modulate all branches of the immune system. It also emphasizes the beneficial metabolic and coagulation-related effects of beta-glucans, making them suitable for larger clinical studies to validate their role as prophylactic vaccine adjuvants and nutritional-based therapeutic supplements against COVID-19.
JOURNAL OF FOOD BIOCHEMISTRY
(2022)
Article
Oncology
Niannian Ji, Neelam Mukherjee, Ryan M. Reyes, Jonathan Gelfond, Martin Javors, Joshua J. Meeks, David J. McConkey, Zhen-Ju Shu, Chethan Ramamurthy, Ryan Dennett, Tyler J. Curiel, Robert S. Svatek
Summary: The combination of oral rapamycin with BCG treatment for NMIBC patients is safe and well-tolerated, enhancing BCG-specific gamma delta T cell immunity and increasing urinary cytokines during BCG treatment. Further research is necessary to explore the long-term safety, tolerability, and efficacy effects of rapamycin in conjunction with BCG.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Review
Oncology
Nazli Dizman, Elizabeth I. Buchbinder
Summary: The review article discusses the role of the CD47/SIRPα axis in cancer, summarizes the efficacy and safety of therapeutics targeting CD47 or SIRPα, and explores the potential future implementation of these treatments for various cancer types.
Article
Oncology
Tracy W. Liu, Seth T. Gammon, Ping Yang, Wencai Ma, Jing Wang, David Piwnica-Worms
Summary: The presence of immune suppressing myeloid cells in the tumor microenvironment limits the success of immune checkpoint therapy (ICT). In this study, the researchers found that removing or inhibiting myeloperoxidase (MPO) can enhance the response to ICT in aged mice with primary melanoma. The tumor microenvironment and systemic immune landscape experienced significant changes, and repurposing MPO-specific inhibitors showed promising results in combination with ICT.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Si-Yu Wu, Yi Xiao, Jin-Li Wei, Xiao-En Xu, Xi Jin, Xin Hu, Da-Qiang Li, Yi-Zhou Jiang, Zhi-Ming Shao
Summary: This study identified two distinct microenvironment phenotypes, 'inflamed' and 'non-inflamed', within the classic basal-like subtype of TNBC, and revealed that MYC amplification and overexpression led to the formation of the non-inflamed TIME. Combination therapy with a DNA methyltransferase inhibitor and immunotherapy reversed T cell exhaustion and improved T cell function, resulting in potent antitumor activity in MYC-overexpressing TNBC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Veterinary Sciences
Simona Sagona, Baldassare Fronte, Francesca Coppola, Elena Tafi, Matteo Giusti, Lionella Palego, Laura Betti, Gino Giannaccini, Lorenzo Guglielminetti, Antonio Felicioli
Summary: Beta-glucans can activate the animal innate immune system and induce stimulatory effects. When administered orally to Apis mellifera workers, beta-glucans did not affect survival rate but increased phenoloxidase activity. The inclusion of beta-glucans in a honey-based diet appeared to enhance phenoloxidase activity in healthy bees. Further research on beta-glucans metabolism in bees and the molecular mechanism of phenoloxidase activation by beta-glucans is needed.
VETERINARY SCIENCES
(2021)
Article
Oncology
Joo Dong Park, Kwang-Soo Kim, Seung Hee Choi, Gae Hoon Jo, Jin-Ho Choi, Si-Won Park, Eun-Su Ko, Minwook Lee, Dae-Keum Lee, Hye Jung Jang, Sohyun Hwang, Hae-Yun Jung, Kyung-Soon Park
Summary: This study found that the ELK3-Mid51 axis is directly associated with mitochondrial dynamics and NK cell immune response in TNBC, providing new strategies to improve the efficacy of NK cell-based immunotherapy of TNBC.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Review
Immunology
Ying Li, Jiao Lv, Weikai Shi, Jia Feng, Mingxi Liu, Shenao Gan, Hongjin Wu, Weiwei Fan, Ming Shi
Summary: Inflammasomes are innate immune mechanisms associated with tumorigenesis and prognosis of cancers. They drive the production of inflammatory cytokines and recruit immune cells to tumor sites.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Louise M. E. Muller, Gemma Migneco, Gina B. Scott, Jenny Down, Sancha King, Basem Askar, Victoria Jennings, Babatunde Oyajobi, Karen Scott, Emma West, Christy Ralph, Adel Samson, Elizabeth J. Ilett, Munitta Muthana, Matt Coffey, Alan Melcher, Christopher Parrish, Gordon Cook, Michelle Lawson, Fiona Errington-Mais
Summary: The study demonstrates that reovirus can reduce MM tumor burden and myeloma-induced bone disease, increase NK cell and CD8(+) T cell numbers, activate these cells, and upregulate effector-memory CD8(+) T cells. Reovirus is able to kill MM cells by activating NK cells and MM-specific CD8(+) T cells, suggesting that reovirus-induced immunotherapy should be combined with agents that enhance antitumor immune responses.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Haibo Sun, Thomas G. Martin, John Marra, Denice Kong, Jonathon Keats, Sandrine Mace, Marielle Chiron, Jeffrey L. Wolf, Jeffrey M. Venstrom, Raja Rajalingam
Summary: The study revealed that specific genetic makeup of patients can influence their response to Isa-lenalidomide-dexamethasone therapy, with patients carrying KIR3DL2 and HLA-A3/11 plus high-affinity FCGR3A-158V allele showing improved progression-free survival. Conversely, patients with KIR2DL1 and HLA-C2C2 combination may have a lower response to this treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Nutrition & Dietetics
B. Scazzocchio, R. Vari, A. Silenzi, S. Giammarioli, A. Masotti, A. Baldassarre, C. Santangelo, M. D'Archivio, C. Giovannini, M. Del Corno, L. Conti, S. Gessani, R. Masella
EUROPEAN JOURNAL OF NUTRITION
(2020)
Review
Oncology
Lucia Conti, Manuela Del Como, Sandra Gessani
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2020)
Article
Oncology
Sabrina Tait, Antonella Baldassarre, Andrea Masotti, Enrica Calura, Paolo Martini, Rosaria Vari, Beatrice Scazzocchio, Sandra Gessani, Manuela Del Corno
FRONTIERS IN ONCOLOGY
(2020)
Review
Oncology
Sandra Gessani, Filippo Belardelli
Summary: Type I interferons play important roles in the regulation of both obesity and cancer, and their dysregulation can lead to different effects on these pathological conditions.
Review
Oncology
Laura Bracci, Alessia Fabbri, Manuela Del Corno, Lucia Conti
Summary: Colorectal cancer is a major global cause of death, and the current medical treatments are not sufficient to control metastatic disease. Combination therapy involving cytotoxic treatments and non-toxic natural compounds is seen as a promising more effective and safer alternative. Polyphenols found in fruit and vegetables have shown potential for enhancing colorectal cancer therapy, but further clinical studies are needed to definitively prove their value.
Review
Cell Biology
Manuela Del Corno, Rosaria Vari, Beatrice Scazzocchio, Barbara Varano, Roberta Masella, Lucia Conti
Summary: Colorectal cancer (CRC) is a major threatening disease with a global incidence expected to increase, where enhanced adiposity, particularly visceral fat, is a major risk factor. Obesity-associated low-grade chronic inflammation is considered a key determinant in CRC development, with fatty acids playing a significant role in regulating adipose tissue homeostasis and immune cell function.
Review
Oncology
Anna Aureli, Manuela Del Corno, Beatrice Marziani, Sandra Gessani, Lucia Conti
Summary: Colorectal cancer is a global health problem with increasing incidence. Galectin-3 (Gal-3) plays a crucial role in the development and progression of CRC, and plant-source food-derived bioactive compounds can help control CRC by inhibiting Gal-3 activity. Studies have shown the direct and immuno-mediated effects of Gal-3 on tumor growth and invasiveness, and its potential as a prognostic biomarker for CRC.
